San Diego, Calif.-based biotech company Blacksmith Medicines announced on Friday it had secured a multimillion-dollar seed funding deal from Eli Lilly and Company and has entered into a research collaboration with the Indianapolis-based pharmaceutical giant to advance human metalloenzyme targets.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,